To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK's Arexvy, Pfizer's Abrysvo and, most recently, Moderna's mResvia. Initially, the CDC said all adults ages 60 and older ...

In its Q3 results, GSK (GSK), the first to receive U.S. approval for an RSV vaccine in May 2023, said its Arexvy vaccine ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

CDC's director, Rochelle Walensky – who is ... saying it will price its Arexvy shot somewhere between $200 and $295. Pfizer said its proposed range of $180 to $270 was subject to revision ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for ... from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in ...

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased ... Changes to ...

The CDC recommends a single dose of either GSK's AREXVY, Moderna's mRESVIA or Pfizer's ABRYSVO for all adults 75 years and ...

“One factor that may help decrease the severity of this year’s RSV season is the availability of new RSV vaccines: Arexvy, ...